Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.49 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.47 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | ATIC | P31939 | 2/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1098417 | 0.84 | LMNA (0.50) | ACLY | |
| SCHEMBL1099660 | 0.82 | GAA (0.46) | KDM4E | |
| SCHEMBL7572129 | 0.77 | GLO1 (0.60) | KDM4EHSD11B1GLO1CYP19A1ACLY | |
| SCHEMBL23200359 | 0.76 | CKS1B (0.44) | KDM4E | |
| SCHEMBL29834262 | 0.76 | CKS1B (0.44) | KDM4E | |
| SCHEMBL29060432 | 0.76 | ABCG2 (0.49) | KDM4E | |
| SCHEMBL1107222 | 0.75 | PLAU (0.54) | KDM4E | |
| SCHEMBL28316252 | 0.73 | LMNA (0.69) | KDM4EHSD11B1CYP19A1ATICAR | |
| SCHEMBL10143577 | 0.73 | GLO1 (0.45) | KDM4EHSD11B1GLO1CYP19A1ACLY | |
| SCHEMBL17687386 | 0.71 | CA2 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-9434711-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2016-09-06 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-23 | — | — | US | disclosed |
| US-8809327-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2014-08-19 | — | — | US | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| EP-2183239-B1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-08-22 | — | — | EP | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | BRANUM SHAWN T (US) | 2012-07-26 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-8153682-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-10 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-10-22 | — | — | US | disclosed |
| WO-2009012430-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190674-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | KDM4E 3266/4885HSD11B1 4304/4885GLO1 3612/4885 |
| US-20140315899-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | KDM4E 3266/4885HSD11B1 4304/4885GLO1 3612/4885 |
| US-20090264474-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM5, TRPM2 | KDM4E 3266/4885HSD11B1 4304/4885GLO1 3612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.